Australia Daily Briefing

Motley Fool highlighted BHP's copper book as the primary differentiation factor heading into its Q2 result — copper is at cycle highs, BHP's copper volumes are growing, and the mining giant's strong run into results suggests institutional investors have pre-positioned for a beat. BHP +0.08% today (essentially flat) is consistent with pre-results positioning discipline — no new buyers ahead of the number. If BHP's copper result matches expectations, it could be the catalyst that brings mining back into the rotation this week, with RIO and FMG likely to follow on sector correlation.

Motley Fool's Monday preview for the ASX 200 flags the key catalysts for the week open: US FOMC decision transmission, RBA policy language, commodities direction, and the first-wave Q2 earnings from ASX heavyweights. For super investors, this is a high-signal week: RBA language on the rate path directly affects fixed-income allocation in SMSF portfolios, and any hawkish surprise reprices Big Four bank dividend yields against term deposits — the core positioning decision for millions of Australian retirees holding a hybrid bank equity / fixed income split.

ResMed — the Sydney-originated sleep apnea device giant — trades at its cheapest multiple in 10 years despite continued earnings growth, per Motley Fool. For ASX healthcare investors, this is a rare value-growth combination: CSL already prices growth (+1.35% today), ResMed offers a contrarian value entry. The decade-low multiple argument is compelling if you believe the GLP-1 weight-loss drug headwind (reducing sleep apnea prevalence) has been fully priced in. The counter-argument: GLP-1 adoption curves still carry a 3-5 year uncertainty tail, meaning the headwind may not have fully worked through the earnings model yet.